1-(4-(trifluoromethyl)phenyl)decan-1-ol

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 1-(4-(trifluoromethyl)phenyl)decan-1-ol
• 英文别名: 1-[4-(Trifluoromethyl)phenyl]decan-1-ol
• 化学式: C₁₇H₂₅F₃O
• 分子量: 302.38
• InChiKey: WNOIYXKIKXZHEU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.5
• 重原子数：
  21
• 可旋转键数：
  9
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.65
• 拓扑面积：
  20.2
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  癸醇 、 对溴三氟甲苯 在 奎宁环 、 potassium phosphate 、 Ir[FCF₃(CF₃)ppy]₂(dtbbpy)PF₆ 、 Nickel(2+);3,4,7,8-tetramethyl-1,10-phenanthroline;dibromide 、 zinc(II) chloride 作用下， 以 二甲基亚砜 为溶剂， 反应 24.0h， 以73%的产率得到1-(4-(trifluoromethyl)phenyl)decan-1-ol
  参考文献：
  名称：

  通过诱导键极化选择性夺取氢原子：通过光氧化还原、HAT 和镍催化对醇进行直接 α-芳基化

  摘要：

  镍金属光氧化还原催化、氢原子转移催化和路易斯酸活化模式的结合，开发了一种用于醇α-羟基C-H键选择性官能化的芳基化方法。该方法采用锌介导的醇去质子化来激活 α-羟基 C-H 键，同时通过抑制醇镍物质的形成来抑制 C-O 键的形成。使用锌基路易斯酸也会使其他氢键失活，例如 α-氨基和 α-氧基 C-H 键。这种方法有助于快速获得苯甲醇，这是药物发现的一个重要主题。药物百忧解的三步合成例证了这种新方法的实用性。

  DOI：

  10.1002/anie.201800749

文献信息

• METHODS FOR INHIBITING HIV-1 REPLICATION INVOLVING THE ADMINISTRATION OF AN ANTI-CCR5 RECEPTOR MONOCLONAL ANTIBODY AND SMALL MOLECULE CCR5 RECEPTOR ANTAGONIST
  申请人：CytoDyn Inc.

  公开号：US20140377259A1

  公开（公告）日：2014-12-25

  This method provides a method for reducing HIV-1 viral load in an HIV-1-infected human subject which comprises administering to the subject at a predefined interval effective HIV-1 viral load-reducing doses of (a) a humanized antibody designated PRO 140, or of (b) an anti-CCR5 receptor monoclonal antibody. This invention also provides a method for inhibiting in a human subject the onset or progression of an HIV-1-associated disorder, the inhibition of which is effected by inhibiting fusion of HIV-1 to CCR5 + CD4 + target cells in the subject. This invention also provides a method for treating a subject infected with HIV-1 comprising administering to the subject (a) a monoclonal antibody which (i) binds to a CCR5 receptor on the surface of the subject's CD4 + cells and (ii) inhibits fusion of HIV-1 to the subject's CCR5 + CD4 + cells, and (b) a non-antibody CCR5 receptor antagonist, in amounts effective to treat the subject.
• USE OF ANTI-CCR5 ANTIBODIES IN GRAFT VERSUS HOST DISEASE
  申请人：CytoDyn Inc.

  公开号：US20170049884A1

  公开（公告）日：2017-02-23

  This composition and method provides for a method for reducing GVHD in a human subject which comprises administering to the subject at a predefined interval effective GVHD-reducing doses of (a) a humanized antibody designated PRO 140, or of (b) an anti-CCR5 receptor monoclonal antibody. This invention also provides a method for inhibiting in a human subject the onset or progression of GVHD. This invention also provides a method for treating a subject with GVHD comprising administering to the subject (a) a monoclonal antibody which (i) binds to a CCR5 receptor on the surface of the subject's CD 4. sup.+ cells, and (b) a non-antibody CCR5 receptor antagonist, in amounts effective to treat the subject.